
Citation: Vincenzo Guarino, Tania Caputo, Rosaria Altobelli, Luigi Ambrosio. Degradation properties and metabolic activity of alginate and chitosan polyelectrolytes for drug delivery and tissue engineering applications[J]. AIMS Materials Science, 2015, 2(4): 497-502. doi: 10.3934/matersci.2015.4.497
[1] | Holly Gaff, Elsa Schaefer . Optimal control applied to vaccination and treatment strategies for various epidemiological models. Mathematical Biosciences and Engineering, 2009, 6(3): 469-492. doi: 10.3934/mbe.2009.6.469 |
[2] | Han Ma, Qimin Zhang . Threshold dynamics and optimal control on an age-structured SIRS epidemic model with vaccination. Mathematical Biosciences and Engineering, 2021, 18(6): 9474-9495. doi: 10.3934/mbe.2021465 |
[3] | Yinggao Zhou, Jianhong Wu, Min Wu . Optimal isolation strategies of emerging infectious diseases with limited resources. Mathematical Biosciences and Engineering, 2013, 10(5&6): 1691-1701. doi: 10.3934/mbe.2013.10.1691 |
[4] | Erika Asano, Louis J. Gross, Suzanne Lenhart, Leslie A. Real . Optimal control of vaccine distribution in a rabies metapopulation model. Mathematical Biosciences and Engineering, 2008, 5(2): 219-238. doi: 10.3934/mbe.2008.5.219 |
[5] | Kento Okuwa, Hisashi Inaba, Toshikazu Kuniya . Mathematical analysis for an age-structured SIRS epidemic model. Mathematical Biosciences and Engineering, 2019, 16(5): 6071-6102. doi: 10.3934/mbe.2019304 |
[6] | Eunha Shim . Optimal strategies of social distancing and vaccination against seasonal influenza. Mathematical Biosciences and Engineering, 2013, 10(5&6): 1615-1634. doi: 10.3934/mbe.2013.10.1615 |
[7] | Toshikazu Kuniya, Taisuke Nakata, Daisuke Fujii . Optimal vaccine allocation strategy: Theory and application to the early stage of COVID-19 in Japan. Mathematical Biosciences and Engineering, 2024, 21(6): 6359-6371. doi: 10.3934/mbe.2024277 |
[8] | Tingting Xue, Long Zhang, Xiaolin Fan . Dynamic modeling and analysis of Hepatitis B epidemic with general incidence. Mathematical Biosciences and Engineering, 2023, 20(6): 10883-10908. doi: 10.3934/mbe.2023483 |
[9] | Yoon-gu Hwang, Hee-Dae Kwon, Jeehyun Lee . Feedback control problem of an SIR epidemic model based on the Hamilton-Jacobi-Bellman equation. Mathematical Biosciences and Engineering, 2020, 17(3): 2284-2301. doi: 10.3934/mbe.2020121 |
[10] | Tingting Ding, Tongqian Zhang . Asymptotic behavior of the solutions for a stochastic SIRS model with information intervention. Mathematical Biosciences and Engineering, 2022, 19(7): 6940-6961. doi: 10.3934/mbe.2022327 |
Within the framework of a nonlocal SIR model, we introduce different vaccination policies and then seek the most effective one. Vaccines are dosed at prescribed ages or at prescribed times to prescribed portions of the susceptible population. The careful choice of the ages, times and individuals to be treated may significantly influence the efficiency of a vaccination campaign. It is thus natural to tackle the resulting optimal control problem, seeking what is in some sense the best vaccination policy.
We denote by $ S = S(t, a) $ the density of individuals at time $ t $ of age $ a $ susceptible to the disease. As usual, $ I = I(t, a) $ is the density of infected individuals at time $ t $ and of age $ a $. The density of individuals that can not be infected by the disease is $ R = R(t, a) $, comprising individuals that recovered as well as those that are, whatever the reason, immune. As a reference to the basic properties of SIR models, originated in [1], see [2,Chapter 6], [3,Chapter 19] or [4,§ 1.5.1].
A possible description of the evolution of $ S $ is provided by the renewal equation [4,Chapter 3] with nonlocal source term
$ ∂tS+∂aS=−(dS(t,a)+∫+∞0λ(a,a′)I(t,a′)da′)S $
|
(1.1) |
where $ d_S = d_S(t, a) \ge 0 $ is the susceptibles' death rate and $ \lambda (a, a') \ge 0 $ quantifies the susceptible individuals of age $ a $ that are infected by individuals of age $ a' $. The nonlocal quantity on the right hand side of (1.1), namely $ \int_0^{+\infty} \lambda(a, a') \; I(t, a') \mathinner{\mathrm{d}{a}}' \, S (t, a) $, represents the total number of susceptible individuals of age $ a $ that become infected at time $ t $ per unit time.
The evolution of the infected portion $ I $ of the population is governed by
$ ∂tI+∂aI=−(dI(t,a)+rI(t,a))I+∫+∞0λ(a,a′)I(t,a′)da′S, $
|
(1.2) |
where $ d_I = d_I(t, a) \geq 0 $ is the death rate of the $ I $ portion of the population and $ r_I = r_I(t, a) \geq 0 $ represents the fraction of infected individuals of age $ a $ that recovers at time $ t $ per unit time. Finally, the evolution of the portion $ R $ of the population that recovers or is unaffected from the disease is
$ ∂tR+∂aR=rI(t,a)I−dR(t,a)R, $
|
(1.3) |
where $ d_R = d_R(t, a) \ge 0 $ is the death rate of the $ R $ population. We assume here that members of the $ R $ population are not dosed with vaccine and that individuals may enter the $ R $ population at birth. In the present setting, dealing with choices different from these latter ones only requires very minor changes and keeps falling in the present general analytic framework.
In a first policy, vaccinations are dosed at any time $ t $ at a time dependent portion $ \eta_j (t) $ of the $ S $ population of the prescribed age $ \bar a_j $, with $ 0 < \bar a_1 < \cdots < \bar a_N $. In this way, the fraction $ \eta_j (t) $ of susceptible population $ S (t, \bar a_j) $ becomes immune. In other words, we use as control the fractions $ \eta_j \colon \mathbb{I} \to [0, 1] $ (for $ j \in \{1, \cdots, N\} $ and $ \mathbb{I} $ being the, possibly unbounded, time interval under consideration). We thus have to supplement the evolution (1.1)–(1.2)–(1.3) with the vaccination conditions
$ S(t,ˉaj+)=(1−ηj(t))S(t,ˉaj−)[∀t, S(t,ˉaj) decreases due to vaccination]I(t,ˉaj+)=I(t,ˉaj−)[the infected population is unaltered]R(t,ˉaj+)=R(t,ˉaj−)+ηj(t)S(t,ˉaj−)[vaccinated individuals are immunized] $
|
(1.4) |
for a.e. $ t > 0 $ and for $ j \in \{1, \cdots, N\} $. A reasonable constraint on the vaccination policy $ \eta $ in (1.4) is that its total cost $ \mathcal{N} (\eta) $ on the considered time interval $ \mathbb{I} $ does not exceed a prescribed maximal cost $ M $. Measuring the total cost by the number $ \mathcal{N} $ of dosed individuals, we have
$ N(η)≤M where N(η)=N∑i=1∫Iηi(t)S(t,ˉai−)dt. $
|
(1.5) |
Alternatively, we also consider vaccination campaigns immunizing an age dependent portion of the whole population at given times $ \bar t_1, \ldots, \bar t_N $. This amounts to substitute (1.4) with
$ S(ˉtk+,a)=(1−νk(a)ηj)S(ˉtk−,a)[∀a, S(ˉtk,a) decreases due to vaccination]I(ˉtk+,a)=I(ˉtk−,a)[the infected population is unaltered]R(ˉtk+,a)=R(ˉtk−,a)+νk(a)S(ˉtk−,a)[vaccinated individuals are immunized] $
|
(1.6) |
where $ \nu_k (a) $ is the percentage of susceptible individuals of age $ a $ that are dosed with the vaccine at time $ \bar t_k $, for $ k = 1, \ldots, N $. Now, a reasonable constraint due to the campaign cost is given by a bound on the number $ \mathcal{N} $ of dosed individuals
$ N(ν)≤M whereN(ν)=N∑i=1∫R+νi(a)S(ˉti−,a)da. $
|
(1.7) |
For simplicity, in both cases above, we assume that $ \eta_j $, respectively $ \nu_i $, represents the percentages of individuals that are successfully vaccinated.
In both cases, our aim is to seek the vaccination campaign that minimizes the total number of infected individuals of all ages over the time interval $ \mathbb{I} $, that is
$ J=∫I∫R+φ(a)I(t,a)dadt $
|
(1.8) |
the function $ \varphi $ being a suitable positive age dependent weight. Here, $ \mathcal{J} $ is a function of $ \eta $ in case (1.4) and of $ \nu $ in case (1.6). In general, in the two cases (1.4) and (1.6), reasonable costs are thus
$ J(η)+N(η)=∫I∫R+φ(a)I(t,a)dadt+N∑j=1∫Iηj(t)S(t,ˉaj−)dt $
|
(1.9) |
$ J(ν)+N(ν)=∫I∫R+φ(a)I(t,a)dadt+N∑i=1∫R+νi(a)S(ˉti−,a)da. $
|
(1.10) |
Clearly, in general, suitable weights can be used to modify the relative relevance of the two costs $ \mathcal{N} $ and $ \mathcal{J} $ in the sums above.
The current literature offers a variety of alternative approaches to similar modeling situations. In the context of models based on ordinary differential equations, that is, without an age structure in the population, this problem has been considered, for instance, already in [5,6,7]. In the recent [8], the vaccination control enters an equation of the type (1.1) through a term $ -u \, S $ in the source on the right hand side of (1.1), implicitly suggesting that vaccination takes place uniformly at all ages. For a recent related investigation focused on cholera, see [9].
The next section summarizes the key analytic properties of the present SIR model, providing the necessary basis to tackle optimal control problems. Section 3 shows the qualitative properties of various vaccination strategies through numerical integrations. Section 4 presents numerical optimizations through the descent method. The paper ends with Section 5.
Denote by $ \mathbb{I} $ either the time interval $ [0, T] $, for a positive $ T $, or $ \left[0, +\infty\right[$. Fix throughout a positive integer $ N $ representing the number of vaccination sessions.
Both models introduced above lead to the initial – boundary value problem
$ {∂tS+∂aS=−(dS(t,a)+∫+∞0λ(a,a′)I(t,a′)da′)S∂tI+∂aI=−(dI(t,a)+rI(t,a))I+∫+∞0λ(a,a′)I(t,a′)da′S∂tR+∂aR=rI(t,a)I−dR(t,a)R $
|
(2.1) |
with initial datum and boundary inflow
$ {S(0,a)=So(a),I(0,a)=Io(a),R(0,a)=Ro(a),a∈R+;S(t,0)=Sb(t),I(t,0)=Ib(t),R(t,0)=Rb(t),t∈I. $
|
(2.2) |
The usual case of the birth terms in the boundary data being assigned through suitable integrals of the populations in reproductive age can be recovered by mainly technical adjustments.
We assume below that the following assumptions are satisfied:
($ {\lambda} $) $ \lambda \in \bf{C}^{0}({\mathbb{R}}^+ \times {\mathbb{R}}^+; {\mathbb{R}}) $ is bounded, with total variation in the first argument uniformly bounded with respect to the second (i.e., $ \sup_{a' \in {\mathbb{R}}^+} \mathinner{{\rm{TV}}} (\lambda(\cdot, a'); {\mathbb{R}}^+) < +\infty $) and Lipschitz continuous in the first argument uniformly with respect to the second (i.e., there exists a $ C > 0 $ such that for all $ a, a_1, a_2 \in {\mathbb{R}}^+ $, $ {\left|{\lambda(a_1, a') - \lambda(a_2, a')}\right|} \leq C \; {\left|{a_1 - a_2}\right|} $).
(d-r) The maps $ d_S, d_I, d_R, r_I \colon \mathbb{I} \times {\mathbb{R}}^+ \to {\mathbb{R}} $ are bounded Caratheodory functions, with $ {\bf{L}^1} $ norm and total variation in $ a $ uniformly bounded in $ t $ (i.e., for $ \varphi = d_S, d_I, d_R, r_I $, $ \sup_{t \in \mathbb{I}} {\left\|{ \varphi (t)}\right\|}_{{\bf{L}^1}({\mathbb{R}}^+; {\mathbb{R}})} < +\infty $ and $ \sup_{t \in \mathbb{I}} \mathinner{{\rm{TV}}} (\varphi (t, \cdot); {\mathbb{R}}^+) < +\infty $) and Lipschitz continuous in $ a $ uniformly in $ t $ (i.e., there exists a $ C > 0 $ such that for all $ t \in \mathbb{I} $ and $ a_1, a_2 \in {\mathbb{R}}^+ $, $ {\left|{ \varphi (t, a_2) - \varphi (t, a_1)}\right|} \leq C \, {\left|{a_2 - a_1}\right|} $).
(IB) The initial datum and the boundary inflow in (2.2) satisfy $ S_o, I_o, R_o \in ({\bf{L}^1} \cap \bf{BV}) ({\mathbb{R}}^+; {\mathbb{R}}^+) $ and $ S_b, I_b, R_b \in ({\bf{L}^1} \cap \bf{BV}) (\mathbb{I}; {\mathbb{R}}^+) $.
For the definition of Caratheodory function, of total variation and of the various functional spaces, we refer for instance to [10]. For all other analytic details specific to the present construction, see [11].
First, we provide the basic well posedness and stability result for the model (2.1)–(2.2) in the case of the vaccination policy (1.4), namely
$ {S(t,ˉaj+)=(1−ηj(t))S(t,ˉaj−)I(t,ˉaj+)=I(t,ˉaj−)R(t,ˉaj+)=R(t,ˉaj−)+ηj(t)S(t,ˉaj−)j=1,…,N. $
|
(2.3) |
Theorem 2.1 ([11]). Under hypotheses ($ {\lambda} $) and (d-r), for any initial and boundary data satisfying (IB), for any choice of the positive vaccination ages $ \bar a_1, \ldots, \bar a_N \in {\mathbb{R}}^+ \setminus \{0\} $ and of the control function $ \eta \in \bf{BV}(\mathbb{I}; [0, 1]^N) $, problem (2.1)–(2.2)–(2.3) admits a unique solution defined on the whole interval $ \mathbb{I} $, depending Lipschitz continuously on the initial datum, through the $ {\bf{L}^1} $ norm, and on $ \eta $, through the $ {{\bf{L}}^\infty } $ norm.
An entirely similar result holds for the vaccination policy (1.6), which we rewrite here as
$ {S(ˉti+,a)=(1−νi(a)ηj)S(ˉti−,a)I(ˉti+,a)=I(ˉti−,a)R(ˉti+,a)=R(ˉti−,a)+νi(a)S(ˉti−,a).i=1,…,N. $
|
(2.4) |
Theorem 2.2 ([11]). Under hypotheses ($ {\lambda} $) and (d-r), for any initial and boundary data satisfying (IB), for any choice of the positive vaccination times $ \bar t_1, \ldots, \bar t_N \in \mathbb{I} \setminus \{0\} $ and of the control function $ \nu \in \bf{BV}({\mathbb{R}}^+; [0, 1]^N) $, problem (2.1)–(2.2)–(2.4) admits a unique solution defined on the whole interval $ \mathbb{I} $, depending Lipschitz continuously on the initial datum, through the $ {\bf{L}^1} $ norm, and on $ \nu $, through the $ {{\bf{L}}^\infty } $ norm.
Below, we restrict the search of optimal controls $ \eta_j $ in (1.4) and $ \nu_i $ in (1.6) to functions of the form
$
ηj(t)=∑mℓ=1ηℓjχ[tℓ−1,tℓ[(t)t0=0,tℓ>tℓ−1,tℓ∈I;νi(a)=∑mℓ=1νℓiχ[aℓ−1,aℓ[(a)a0=0,aℓ>aℓ−1,aℓ∈R+.
$
|
The stability results above ensure that the costs (1.5), (1.7) and (1.8) are Lipschitz continuous functions of the various $ \eta^\ell_j $ and $ \nu^\ell_i $. Hence, a straightforward Weierstraß argument proves the existence of optimal controls minimizing the costs (1.9) or (1.10).
We refer to [11] for the detailed proofs as well as for further stability estimates on the dependence of the solutions on the various parameters.
We now compare different instances of both strategies (2.3) and (2.4) by means of numerical integrations.
In all the integrations below, for the convective part we exploit the upwind method [12,§ 4.8] with mesh size $ \Delta a = 2.5\cdot 10^{-3} $ along the age axis and $ \Delta t = 1.25\cdot 10^{-3} $ along the time axis. The integrals in the right hand side in (2.1) are computed via a rectangle rule and a fractional step method [12,§ 17.1] allows to combine the convective evolution with the source term. The time axis $ a = 0 $ belongs both to the physical boundary and to the numerical one, its treatment being straightforward since all characteristics move inward the domain $ \mathbb{I} \times {\mathbb{R}}^+ $, so that the value of the boundary data can be assigned to the solution. On the other side, along the numerical boundary $ a = 10 $, the usual free flow conditions is consistent with all characteristic speeds being positive.
Our aim in the integrations below is to clearly show the qualitative properties of the model (2.1). Indeed, we do not claim that the chosen numerical values are realistic. In particular, the most adequate units for $ t $ and $ a $ might well be different.
With reference to the Cauchy problem (2.1)–(2.2) and to the costs (1.9)–(1.10), we use throughout the following parameters and functions:
$ ds(t,a)=14a1+a,dI(t,a)=12a1+a,dR(t,a)=14a1+a,rI(t,a)=110,λ(a,a′)=2e−|a−a′|/2,φ(a)=1. $
|
(3.1) |
The mortality rates are increasing with age and higher for the infected population. The choice of $ \lambda $ assumes that the infection propagates preferably among individuals of similar age.
We consider two different initial data, first the case without infection, i.e.,
$ So(a)=3(1−a10),Io(a)=0,Ro(a)=(1−a10), $
|
(3.2) |
and then a case with a $ 20\% $ of infected individuals, with respect to the $ S $ population, at time $ t = 0 $, that is
$ So(a)=2.5(1−a10),Io(a)=0.5(1−a10),Ro(a)=(1−a10). $
|
(3.3) |
Both these initial data are linearly decreasing with age. Note that the total initial population is the same in the two cases (3.2) and (3.3).
Natality is chosen so that no jump appears between the initial values at $ a = 0+ $ in (3.2) and the boundary data at $ t = 0+ $:
$ Sb(t)=3,Ib(t)=0,Rb(t)=1, $
|
(3.4) |
where we assume that no individuals are infected already at birth.
We first consider two extreme situations to be later used for comparisons, namely corresponding to no illness (3.2), and to a spreading illness with no vaccination strategy whatsoever.
In other words, we integrate (2.1)–(2.2)–(3.1) first setting $ I_o \equiv 0 $, so that for all times $ t $, $ I (t) \equiv 0 $ and no illness ever appears, and then setting $ I_o $ as in (3.3) but dose no vaccination, so that the epidemic spreads uncontrolled. The results of these two integrations are displayed in Figure 1. The two solutions are, clearly, entirely different. When $ I \equiv 0 $, a sort of dynamic equilibrium is reached, the resulting contour plot being approximately invariant with respect to translation along the vertical $ t $ axis. The presence of the $ I $ population in the initial datum leads to the spread of the disease and eventually to a dramatic population decrease.
We consider now a simple vaccination strategy consisting in a single campaign, dosing vaccination at a single age $ \bar a $ for all times.
As it is to be expected, the earlier vaccinations are dosed, the better it is in terms of the cost (1.8). In Figure 2 the ratio of the number of infected individuals vs. the total population corresponding to the vaccinations ages $ \bar a = 0.1, \; 0.3, \; 0.5, \; 1.5 $ are portrayed. The leftmost contour plot shows the effects of a very early vaccination, clearly far more effective than later doses.
The striking effect of this early age vaccination is confirmed in Figure 3, where we display the sum $ S+R $ as a function of $ t $ and $ a $ in the same cases of the vaccinations ages $ \bar a = 0.1, \; 0.3, \; 0.5, \; 1.5 $. Clearly, due to the form of the vaccination condition (2.3) and to the present smooth data (3.3)–(3.4), the sum $ S+R $ is continuous across $ \bar a $. In the leftmost diagram, the healthy population apparently recovers from the spread of the disease. When vaccinations are dosed at a later age, i.e., in the three diagrams on the right, the relatively large portion of individuals initially vaccinated survive the disease, but juveniles get infected resulting in the solitary waves, consisting essentially of the $ R $ population, shown in Figure 3.
The counterpart of these solitary waves is the propagating "hole" in Figure 2.
In other words, the vaccination campaign at the age $ \bar a = 0.5 $ looks as (un)successful as the campaign at $ \bar a = 1.5 $. On the contrary, dosing at $ \bar a = 0.1 $ is by far more effective.
Indeed, this strategy keeps the density of the susceptible population in (2.1) very low due to (2.3). Hence, also the nonlocal source term, which is proportional to $ S $, is relatively small and infection hardly spreads. When vaccination is dosed at higher ages, the nonlocal source term is able to bring infection at low ages, thus making the vaccination policy far less effective.
Table 1 confirms that, in particular for what concerns the total number of infected individuals, by far, the best strategy is the one dosing vaccines at the earliest considered age $ \bar a = 0.1 $. This choice also results in the highest number of vaccinated individuals, so that also $ \mathcal{N} $ corresponds to the most expensive policy.
$ \bar a $ in (2.3) | 0.1 | 0.2 | 0.3 | 0.5 | 1.0 | 1.5 | none |
$ \mathcal{J} $ in (1.8) | 33.48 | 41.03 | 44.73 | 46.85 | 47.39 | 47.51 | 48.30 |
$ \mathcal{N} $ in (1.5) | 10.53 | 5.05 | 2.30 | 0.76 | 0.41 | 0.36 | 0.00 |
$ \mathcal{J}+\mathcal{N} $ in (1.9) | 44.01 | 46.08 | 47.03 | 47.61 | 47.80 | 47.87 | 48.30 |
We now simulate another single vaccination campaign, consisting in dosing all individuals of all ages at a given time $ \bar t $, see Figure 4.
Similarly to the integration detailed in § 3.2, campaigns at earlier times results in being more effective. The choices $ \bar t = 0.5 $ and $ \bar t = 1.5 $ are quite similar to each other and, in the lower right part of the $ (a, t) $–plane, to the situation with no vaccination campaign whatsoever, as it stems from a comparison between the two rightmost diagram in Figure 4 and the rightmost one in Figure 1, see also Table 2.
$ \bar t $ in (2.4) | 0.1 | 0.2 | 0.3 | 0.5 | 1.0 | 1.5 | none |
$ \mathcal{J} $ in (1.8) | 31.71 | 38.80 | 43.65 | 46.79 | 47.40 | 47.42 | 48.30 |
$ \mathcal{N} $ in (1.7) | 9.37 | 5.46 | 2.74 | 0.86 | 0.40 | 0.39 | 0.00 |
$ \mathcal{J}+\mathcal{N} $ in (1.10) | 41.08 | 44.26 | 46.39 | 47.66 | 47.80 | 47.80 | 48.30 |
Note that the present strategy is far less effective: vaccinations are dosed only at the given time $ \bar t $, after which the disease spreads completely out of control, see Figure 5.
The values of the costs (1.7), (1.8) and (1.10) presented in Table 2 show that vaccinating the whole $ S $ population at $ \bar t = 0.5 $ or later, makes relatively small difference, the most convenient choice being at the earliest time $ \bar t = 0.1 $. Similarly to what happens in § 3.2, vaccinating all susceptible individuals at $ \bar t = 0.1 $ makes the susceptible portion of the population very small wherever $ a > t - \bar t $, thus essentially canceling the nonlocal source term which represents the spreading of the disease.
We note however an evident key difference between the best vaccination age choice (i.e., $ \bar a = 0.1 $) in § 3.2 and the present best vaccination time choice (i.e., $ \bar t = 0.1 $). The latter one yields lower values of the chosen costs. However, as time grows, the former strategy is prone to by far preferable evolutions. Indeed, the leftmost diagram in Figure 2 (corresponding to $ \bar a = 0.1 $) clearly shows a decreasing $ I $ population, while it is increasing in the latter strategy, see Figure 4, left (corresponding to $ \bar t = 0.1 $).
We now consider in more detail the search for an optimal vaccination strategy in a slightly different setting. First, we assume that infection among individuals of different ages is somewhat more difficult, slightly modifying (3.1) to
$ ds(t,a)=14a1+a,dI(t,a)=12a1+a,dR(t,a)=14a1+a,rI(t,a)=110,λ(a,a′)=e−2|a−a′|,φ(t)=1, $
|
(4.1) |
and choose the initial datum
$ So(a)={3.0(1−a10)a∈[0,3]∪[5,10]1.5(1−a10)a∈]3,5[Io(a)={0a∈[0,3]∪[5,10]1.5(1−a10)a∈]3,5[Ro(a)=(1−a10). $
|
(4.2) |
corresponding to an initial infected population that amounts to $ 50\% $ of the susceptible population in the age interval $ \left]3, 5\right[$. As boundary data, we keep the choice (3.4), corresponding to a constant natality rate for the $ S $ and $ R $ populations, and to no one being infected at birth.
As a first reference situation, we consider the case of no vaccination being dosed to anyone. The resulting integration is displayed in Figure 6. In this reference case, the total number of infected individuals is $ 22.77 $.
We only remark that Figure 6 shows a typical effect of the nonlocality of the source terms in (2.1). There is an increase in the $ I $ population for, approximately, $ t \geq 3 $ and $ a \in [1, 3]$ due to the transmission and growth of the infection, a feature which becomes relevant in regions close to (relatively) high values of the susceptible population $ S $.
Below we restrict the values of the percentages $ \eta_j $ and $ \nu_i $ in (2.3) and (2.4) to the interval $ [0, 0.8] $. Indeed, it is reasonable to assume that not every individual can be vaccinated and that, in some cases, vaccination may fail to immunize a small percentage of susceptible individuals. For the sake of simplicity, we introduce only three vaccination ages $ \bar a_1 $, $ \bar a_2 $ and $ \bar a_3 $ or times $ \bar t_1 $, $ \bar t_2 $ and $ \bar t_3 $.
We present both sample values of the costs (1.9)–(1.10) and the results of optimization procedures. The former correspond to dosing vaccines to $ 60\% $ or $ 80\% $ of the $ S $ population at each prescribed age for all times, or at each prescribed time at all ages. The latter are achieved through the usual descent method, see [13,§ 7.2.2], with suitable projections that restrict to values of $ \eta_1, \eta_2, \eta_3 $ and $ \nu_1, \nu_2, \nu_3 $ in $ [0, 0.8] $. A formal justification of the use of this method is in the Lipschitz continuous dependence of the cost (1.9) or (1.10) on the various parameters, see [11].
In the integrations below, we keep $ \Delta a = 2.5 \cdot 10^{-3} $ and $ \Delta t = 1.25 \cdot 10^{-3} $. However, due to computing time limitations, when applying the steepest descent method we passed to coarse meshes, where $ \Delta a = 5 \cdot 10^{-2} $ and $ \Delta t = 2.5 \cdot 10^{-2} $. Correspondingly, in case of the controls (2.3), optimal controls are sought in the class of locally constant functions of the type $ \eta_j (t) = \sum_{\ell = 1}^{20} \eta^\ell_j \, {\chi_{ {[(\ell-1) /4, \, \ell/4[}}} (t) $. An entirely similar procedure is followed in the case of the age dependent controls (2.4). For completeness, we recall that in the present merely Lipschitz continuous setting, the steepest descent (or gradient) method needs not converge and, even if it does, its limit may well be different from a point of minimum. Therefore, in our application of this method, we keep checking that the values of the cost (do indeed) decrease, but we can not ensure that the values obtained are indeed points of minimum.
Now, in the model (2.1)–(2.2) with parameters (4.1), initial datum (4.2) and boundary datum (3.4) we prescribe $ 3 $ vaccination ages and, correspondingly, $ 3 $ constant values of the percentage of vaccinated individuals, so that, with reference to the notation (2.3),
$ ˉa1=2.0,ˉa2=4.0,ˉa3=6.0 and ηj∈{0.6,0.8} for j=1,2,3. $
|
(4.3) |
First, we perform the resulting $ 8 $ numerical integrations and record the resulting costs (1.5), (1.8) and (1.9). Then, these costs are compared among each other and with the costs resulting from the steepest descent method. The numerical values obtained are in Table 3.
$ \eta_1 $ | $ \eta_2 $ | $ \eta_3 $ | $ \mathcal{J} $ as in (1.8) | $ \mathcal{N} $ as in (1.5) | $ \mathcal{J} + \mathcal{N} $ as in (1.9) |
$ 0.6 $ | $ 0.6 $ | $ 0.6 $ | $ 14.54 $ | $ 7.56 $ | $ 22.11 $ |
$ 0.6 $ | $ 0.6 $ | $ 0.8 $ | $ 14.38 $ | $ 7.87 $ | $ 22.25 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.6 $ | $ 14.18 $ | $ 8.02 $ | $ 22.20 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.8 $ | $ 14.02 $ | $ 8.31 $ | $ 22.83 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.6 $ | $ 13.12 $ | $ 9.22 $ | $ 22.34 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.8 $ | $ 12.96 $ | $ 9.52 $ | $ 22.48 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.6 $ | $ 12.80 $ | $ 9.60 $ | $ 22.40 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.8 $ | $ 12.64 $ | $ 9.88 $ | $ 22.53 $ |
see Figure 8 | $ 16.01 $ | $ 4.67 $ | $ 20.69 $ |
As is to be expected, the lowest amount of infected individuals results from the highest (and most expensive) vaccination dosing, detailed in Figure 7. There, the discontinuities in $ S $ across the ages $ \bar a_j $ resulting from the conditions (2.3) are clearly visible. Choosing $ \bar a_1 = 2.0 $ as the lowest vaccination age allows, for about $ t \geq 4 $, that individuals younger that this age are infected and, at later times, the disease may well spread among juveniles.
The steepest descent procedure yields a value of the cost $ \mathcal{J} + \mathcal{N} $ in (1.9) lower than any of the ones obtained with constant $ \eta_j $ as in (4.3), see Table 3. The optimal controls found by means of the steepest descent method are shown in Figure 8 and the corresponding solutions are in Figure 9.
We now follow a procedure, in a sense, analogous to that detailed in the preceding Paragraph 4.1. Choose the times and controls
$ ˉt1=0.5,ˉt2=1.0,ˉt3=1.5 and νi∈{0.6,0.8} for i=1,2,3. $
|
(4.4) |
The costs of the integrations resulting from these choices and from the optimization are collected in Table 4. Again, the lowest number of infected individuals is obtained with the highest number of vaccinations and the corresponding solutions are plotted in Figure 10. Given that infected individuals can not turn back susceptible, it is clear that the first vaccination of $ 80\% $ of all susceptible individuals greatly hinders the spreading of the disease. The later vaccinations, dosed also to the newly born individuals, block further infections, see Figure 10.
$ \nu_1 $ | $ \nu_2 $ | $ \nu_3 $ | $ \mathcal{J} $ as in (1.8) | $ \mathcal{N} $ as in (1.7) | $ \mathcal{J} + \mathcal{N} $ as in (1.10) |
$ 0.6 $ | $ 0.6 $ | $ 0.6 $ | $ 6.41 $ | $ 13.05 $ | $ 19.47 $ |
$ 0.6 $ | $ 0.6 $ | $ 0.8 $ | $ 6.23 $ | $ 13.75 $ | $ 19.98 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.6 $ | $ 6.17 $ | $ 13.60 $ | $ 19.77 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.8 $ | $ 6.06 $ | $ 14.10 $ | $ 20.16 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.6 $ | $ 5.78 $ | $ 13.89 $ | $ 19.66 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.8 $ | $ 5.67 $ | $ 14.44 $ | $ 20.12 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.6 $ | $ 5.66 $ | $ 14.22 $ | $ 19.88 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.8 $ | $ 5.59 $ | $ 14.65 $ | $ 20.24 $ |
see Figure 11 | $ 7.80 $ | $ 8.18 $ | $ 15.98 $ |
The strategy found through the steepest descent method, shown in Figure 11, clearly takes advantage of the particular shape of the initial datum (4.2). Indeed, the two "humps" in $ \nu_2 $ and $ \nu_3 $ roughly correspond to the wave of infected individuals propagating from $ t = 0 $ onward.
As a consequence, note that the optimal control $ \nu_3 $ vanishes for small ages. This is due to the fact that newborn are healthy and that the preceding vaccination campaigns succeeded in avoiding the transmission of the infection to the youngest part of the population, see Figure 12.
With the data chosen in (4.1) and the parameters (4.2), the best vaccination strategies turn out to be the ones of the type (2.4), i.e., those where a percentage $ \nu_i (a) $ of all susceptible individuals of age $ a $ are dosed at time $ \bar t_i $, as it stems out comparing Table 3 with Table 4. Clearly, this outcome is a consequence of the particular choices in (4.1) and (4.2), but the framework based on (2.1) and (2.3) or (2.4), and its amenability to optimization procedure, is independent of these choices.
We addressed the issue of optimizing vaccination strategies. Sample numerical integrations show various features of the solutions to the integro–differential model (2.1)–(2.2) and the effects of different choice of the controls $ \eta_j $ in (2.3) or $ \nu_i $ in (2.4). Standard numerical optimization procedures, such as the steepest descent method, can be applied to single out optimal choices of the controls.
The present framework is amenable to a variety of different applications and extensions, only a minor part of which were explicitly considered above. For instance, natality, which is represented by the boundary datum, can be assigned as a function of the present, or past, population densities, also allowing for newborn to be infected also at birth. The present age structured formulation allows to take into account the possibility that the disease is transmitted differently in different age groups. Introducing in the $ S $, $ I $ or $ R $ populations sexual distinctions only amounts to consider more equations, the basic analytic framework in [11] remaining essentially unaltered.
Part of this work was supported by the PRIN 2015 project Hyperbolic Systems of Conservation Laws and Fluid Dynamics: Analysis and Applications and by the GNAMPA 2018 project Conservation Laws: Hyperbolic Games, Vehicular Traffic and Fluid dynamics.
The IBM Power Systems Academic Initiative substantially contributed to the numerical integrations.
The authors declare there is no conflict of interest.
[1] | Robyt J (2001) Polysaccharides: energy storage. John Wiley & Sons. |
[2] |
Wang HM, Loganathan D, Linhardt RJ (1991) Determination of the pKa of glucuronic acid and the carboxy groups of heparin by 13C-nuclear-magnetic-resonance spectroscopy. Biochem J 278: 689-95. doi: 10.1042/bj2780689
![]() |
[3] | Kyte J (1995) Structure in protein chemistry. New Yorg: Garland Publishing Inc. |
[4] |
Crouzier T, Boudou T, Picart C (2010) Polysaccharide-based polyelectrolyte multilayers. Curr Opin Colloid In 15: 417-426. doi: 10.1016/j.cocis.2010.05.007
![]() |
[5] |
Shukla RK (2011) Carbohydrate Molecules: An Expanding Horizon in Drug Delivery and Biomedicine. Crit Rev Ther Drug Carrier Syst 28: 255-292. doi: 10.1615/CritRevTherDrugCarrierSyst.v28.i3.20
![]() |
[6] | Dumitriu S (2004) Polysaccharides: Structural Diversity and Functional Versatility. Second Edition Marcel Dekker: New York. |
[7] | Andresen IL, Skipnes O, Smidsrod O, et al. (1977) Some biological functions of matrix components in benthic algae in relation to their chemistry and the composition of seawater. ACS SymSer 48: 361-381. |
[8] | Sadoff HL (1975) Encystment and germination in Azotobactervinelandii. Bacteriol Rev 39: 516-539. |
[9] |
Haug A, Larsen B, Smidsrød O (1966) A Study of the Constitution of Alginic Acid by Partial Acid Hydrolysis. Acta Chem Scand 20: 183-190. doi: 10.3891/acta.chem.scand.20-0183
![]() |
[10] | Simionescu CI, Popa VI, Rusan V, et al. (1976) The influence of structural units distribution on macromolecular conformation of alginic acid. Cell Chem Technol 10: 587-594. |
[11] | Min KH, Sasaki SF, Kashiwabara Y, et al. (1977) Fine structure of SMG alginate fragment in the light of its degradation by alginate lyases of Pseudomonas sp. J Biochem 81: 555-562. |
[12] | Harding SE, Varum KM, Stokke BT, et al. (1991) Molecular weight determination of polysaccharides. Adv Carbohydr Anal 1:63-144. |
[13] |
Martinsen A, Skjåk-Bræk G, Smidsrød O (1991) Comparison of different methods for determination of molecular weight and molecular weight distribution of alginates. Carbohydr Polym 15: 171-193. doi: 10.1016/0144-8617(91)90031-7
![]() |
[14] |
Smidsrød O, Haug A (1968) Dependence upon uronic acid composition of some ion-exchange properties of alginates. Acta Chem Scand 22:1989-1997. doi: 10.3891/acta.chem.scand.22-1989
![]() |
[15] |
Sikorski P, Mo F, Skjåk-Bræk G, et al. (2007) Evidence for Egg-Box-Compatible Interactions in Calcium−Alginate Gels from Fiber X-ray Diffraction. Biomacromolecules 8: 2098-2103. doi: 10.1021/bm0701503
![]() |
[16] |
Haug A, Smidsrod O (1970) Selectivity of some anionic polymers for divalent metal ions. Acta Chem Scand 24: 843-854. doi: 10.3891/acta.chem.scand.24-0843
![]() |
[17] |
Haug A, Myklestad S, Larsen B, et al. (1967) Correlation between chemical structure and physical properties of alginates. Acta Chem Scand 21: 768-778. doi: 10.3891/acta.chem.scand.21-0768
![]() |
[18] |
Grasselli M, Diaz LE, Cascone O (1993) Beaded matrices from cross-linked alginate for affinity and ion exchange chromatography of proteins. Biotechnol Tech 7: 707-712. doi: 10.1007/BF00152617
![]() |
[19] |
Pawar SN, Edgar KJ (2012) Alginate derivatization: a review of chemistry, properties and application. Biomaterials 33: 3279-3305. doi: 10.1016/j.biomaterials.2012.01.007
![]() |
[20] |
Hari PR, Chandy T, Sharma CP (1996) Chitosan/calcium alginate beads for oral delivery of insulin. J Appl Polym Sci 59: 1795-1801. doi: 10.1002/(SICI)1097-4628(19960314)59:11<1795::AID-APP16>3.0.CO;2-T
![]() |
[21] |
Huguet ML, Groboillot A, Neufeld RJ, et al. (1994) Hemoglobin encapsulation in chitosan/calcium alginate beads. J Appl Polym Sci 51: 1427-1432. doi: 10.1002/app.1994.070510810
![]() |
[22] |
MiFL, Sung HW, Shyu SS (2002) Drug release from chitosan-alginate complex beads reinforced by a naturally occurring crosslinking agent. Carbohydr Polym 48: 61-72. doi: 10.1016/S0144-8617(01)00212-0
![]() |
[23] |
Chan AW, Whitney RA, Neufeld R (2009) Semisynthesis of a controlled stimuli-responsive alginate hydrogel. Biomacromolecules 10: 609-616. doi: 10.1021/bm801316z
![]() |
[24] |
Bhattarai N, Zhang M (2007) Controlled synthesis and structural stability of alginate-based nanofibers. Nanotechnology 18: 455601-455611. doi: 10.1088/0957-4484/18/45/455601
![]() |
[25] |
Bouhadir KH, Hausman DS, Mooney DJ (1999) Synthesis of cross-linked poly(aldehyde guluronate) hydrogels. Polymer 40: 3575-3584. doi: 10.1016/S0032-3861(98)00550-3
![]() |
[26] |
Xu JB, Bartley JP, Johnson RA (2003) Preparation and characterization of alginate hydrogel membranes crosslinked using a water-soluble carbodiimide. J Appl Polym Sci 90: 747-753. doi: 10.1002/app.12713
![]() |
[27] |
Boontheekul T, Kong HJ, Mooney DJ (2005) Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 26: 2455-2465. doi: 10.1016/j.biomaterials.2004.06.044
![]() |
[28] |
Gomez CG, Rinaudo M, Villar MA (2007) Oxidation of sodium alginate and characterization of the oxidized derivatives. Carbohydr Polym 67: 296-304. doi: 10.1016/j.carbpol.2006.05.025
![]() |
[29] |
Kang HA, Jeon GJ, Lee MY, et al. (2002) Effectiveness test of alginate-derived polymeric surfactants. J Chem Technol Biot 77: 205-210. doi: 10.1002/jctb.550
![]() |
[30] |
Kang HA, Shin MS, Yang JW (2002) Preparation and characterization of hydrophobically modified alginate. Polym Bull 47: 429-435. doi: 10.1007/s002890200005
![]() |
[31] |
Laurienzo P, Malinconico M, Motta A, et al. (2005) Synthesis and characterization of a novel alginate-poly(ethylene glycol) graft copolymer. Carbohydr Polym 62: 274-282. doi: 10.1016/j.carbpol.2005.08.005
![]() |
[32] |
Skjåk-Bræk G, Zanetti F, Paoletti S (1989) Effect of acetylation on some solution and gelling properties of alginates. Carbohydr Res 185: 131-138. doi: 10.1016/0008-6215(89)84028-5
![]() |
[33] |
Coleman RJ, Lawrie G, Lambert LK, et al. (2011) Phosphorylation of alginate: synthesis, characterization, and evaluation of in vitro mineralization capacity. Biomacromolecules 12: 889-897. doi: 10.1021/bm1011773
![]() |
[34] |
Freeman I, Kedem A, Cohen S (2008) The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials 29: 3260-3268. doi: 10.1016/j.biomaterials.2008.04.025
![]() |
[35] |
Sand A, Yadav M, Mishra DK, et al. (2010) Modification of alginate by grafting of N-vinyl-2-pyrrolidone and studies of physicochemical properties in terms of swelling capacity, metal-ion uptake and flocculation. Carbohydr Polym 80: 1147-1154. doi: 10.1016/j.carbpol.2010.01.036
![]() |
[36] |
Sinquin A, Hubert P, Dellacherie E (1993) Amphiphilic derivatives of alginate: evidence for intra-and intermolecular hydrophobic associations in aqueous solution. Langmuir 9: 3334-3337. doi: 10.1021/la00036a002
![]() |
[37] |
Yang JS, Zhou QQ, He W (2013) Amphipathicity and self-assembly behavior of amphiphilic alginate esters. Carbohydr Polym 92: 223-227. doi: 10.1016/j.carbpol.2012.08.100
![]() |
[38] |
Mahou R, Meier RPH, Bühler LH, et al. (2014) Alginate-Poly(ethylene glycol) Hybrid Microspheres for Primary Cell Microencapsulation. Materials 7: 275-286. doi: 10.3390/ma7010275
![]() |
[39] |
Bernkop-Schnurch A, Kast CE, Richter MF (2001) Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine. J Controlled Release 71: 277-285. doi: 10.1016/S0168-3659(01)00227-9
![]() |
[40] |
Jindal AB, Wasnik MN, Nair HA (2010) Synthesis of thiolated alginate and evaluation of mucoadhesiveness, cytotoxicity and release retardant properties. Indian J Pharm Sci 72: 766-774. doi: 10.4103/0250-474X.84590
![]() |
[41] | Leone G, Torricelli P, Chiumiento A, et al. (2008) Amidic alginate hydrogel for nucleus pulposus replacement. J Biomed Mater Res A 84: 391-401. |
[42] |
Vallée F, Müller C, Durand A, et al. (2009) Synthesis and rheological properties of hydrogels based on amphiphilic alginate-amide derivatives. Carbohydr Res 344: 223-228. doi: 10.1016/j.carres.2008.10.029
![]() |
[43] | Coates EE, Riggin CN, Fishe JP (2013) Photocrosslinked alginate with hyaluronic acid hydrogels as vehicles for mesenchymal stem cell encapsulation and chondrogenesis. J Biomed Mater Res A 101: 1962-1970. |
[44] |
Kumar MN, Muzzarelli RAA, Muzzarelli C, et al. (2004) Chitosan chemistry and pharmaceutical perspectives. Chem Rev 104: 6017-84. doi: 10.1021/cr030441b
![]() |
[45] |
Zhao Y, Park RD, Muzzarelli RAA (2010) Chitin Deacetylases: Properties and Applications. Mar Drugs 8: 24-46. doi: 10.3390/md8010024
![]() |
[46] | Trzcinski S (2006) Combined degradation of chitosan. Polish Chitin Society Monograph XI, 103-11. |
[47] |
Varum KM, Ottoy MH, Smidsrød O (1994) Water solubility of partially N-acetylated chitosan as a function of pH: effect of chemical composition and depolymerization. Carbohydr Polyms 25: 65-70. doi: 10.1016/0144-8617(94)90140-6
![]() |
[48] | Knaul JZ, Kasaai MR, Bui VT, et al. (1998) Characterization of deacetylated chitosan and chitosan molecular weight review. Can J Chem 76: 1699-1706. |
[49] | Chattopadhyay DP, Inamdar MS (2010) Aqueous behavior of chitosan. Int Polym Science 2010 doi:10.1155/2010/939536. |
[50] | Roberts GAF (1992) Chitin Chemistry. Houndmills UK: Macmillan Press. |
[51] |
An HK, Park BY, Kim DS (2001) Crab shell for the removal of heavy metals from aqueous solutions. Water Res 35: 3551-3556. doi: 10.1016/S0043-1354(01)00099-9
![]() |
[52] |
Wang QZ, Chen XG, Liu N, et al. (2006) Protonation constants of chitosan with different molecular weight and degree of deacetylation. Carbohydr Polym 65: 194-201. doi: 10.1016/j.carbpol.2006.01.001
![]() |
[53] |
Rinaudo M (2006) Chitin and chitosan: Properties and applications. Prog Polym Sci 31: 603-632. doi: 10.1016/j.progpolymsci.2006.06.001
![]() |
[54] | Baxter A, Dillon M, Taylor KD, et al. (1992) Improved method for I.R. determination of the degree of N-acetylation of chitosan. Int J Biol Macromol 14: 166-169. |
[55] |
Muzzarelli RAA, Rochetti R (1985) Determination of the degree of acetylation of chitosans by first derivative ultraviolet spectrophotometry. Carbohydr Polym 5: 461-472. doi: 10.1016/0144-8617(85)90005-0
![]() |
[56] |
Vårum KM, Anthonsen MW, Grasdalen H, et al. (1991) Determination of the degree of N-acetylation and the distribution of N-acetyl groups in partially N-deacetylated chitins (chitosans) by high-field n.m.r. spectroscopy. Carbohydr Res 211:17-23. doi: 10.1016/0008-6215(91)84142-2
![]() |
[57] |
Värum KM, Anthonsen MW, Grasdalen H, et al. (1991) 13C-NMR studies of the acetylation sequences in partially N-deacetylated chitins (chitosans). Carbohydr Res 217: 19-27. doi: 10.1016/0008-6215(91)84113-S
![]() |
[58] |
Kasaai MR (2010) Determination of the degree of N-acetylation for chitin and chitosan by various NMR spectroscopy techniques: A review. Carbohydr Polym 79: 801-810. doi: 10.1016/j.carbpol.2009.10.051
![]() |
[59] | Sreenivas SA, Pai KV (2008) ThiolatedChitosans: novel polymers for mucoadhesive drug delivery -A Review. Trop J Pharm Res 7: 1077-1088. |
[60] |
Jayakumar R, Nwe N, Tokura S, et al. (2007) Sulfated chitin and chitosan as novel biomaterials. Int J Biol Macromol 40: 175-181. doi: 10.1016/j.ijbiomac.2006.06.021
![]() |
[61] |
Sashiwa H, Kawasaki N, Nakayama A (2002) Synthesis of water-soluble chitosan derivatives by simple acetylation. Biomacromolecules 3: 1126-1128. doi: 10.1021/bm0200480
![]() |
[62] | Jayakumar R, Reis RL, Mano JF (2006) Chemistry and Applications of Phosphorylated Chitin and Chitosan. e-Polymers 6: 447-462. |
[63] |
Jayakumar R, Nagahama H, Furuike T, et al. (2008) Synthesis of phosphorylated chitosan by novel method and its characterization. Int J Biol Macromol 42: 335-339. doi: 10.1016/j.ijbiomac.2007.12.011
![]() |
[64] |
Rúnarsson ÖV, Holappa J, Jónsdóttir S, et al. (2008) N-selective “one pot” synthesis of highly N-substituted trimethyl chitosan (TMC). Carbohydr Polym 74: 740-744. doi: 10.1016/j.carbpol.2008.03.008
![]() |
[65] |
Rosenthal R, Günzel D, Finger C, et al. (2012) The effect of chitosan on transcellular and paracellular mechanisms in the intestinal epithelial barrier. Biomaterials 33: 2791-2800. doi: 10.1016/j.biomaterials.2011.12.034
![]() |
[66] |
Muzzarelli RAA, Tanfani F, Emanuelli M, et al. (1982) N-(Carboxymethylidene) chitosans and N-(Carboxymethyl)-chitosans: Novel Chelating Polyampholytes obtained from Chitosan Glyoxylate. Carbohydr Res 107: 199-214. doi: 10.1016/S0008-6215(00)80539-X
![]() |
[67] |
Mourya VK, Inamdar NN, Tiwari A (2010) Carboxymethyl chitosan and its applications. Adv Mat Lett 1: 11-33. doi: 10.5185/amlett.2010.3108
![]() |
[68] |
George M, Abraham TE (2006) Polyionic Hydrocolloids forma the intestinal delivery of protein drugs: Alginate and chitosan-A review. J Controlled Release 114: 1-14. doi: 10.1016/j.jconrel.2006.04.017
![]() |
[69] |
Alves NM, Mano JF (2008) Chitosan derivatives obtained by chemical modification for biomedical and enviromental application. Int J Biol Macromol 43: 401-414. doi: 10.1016/j.ijbiomac.2008.09.007
![]() |
[70] |
Riva RL, Ragelle H, des Rieux A, et al. (2011) Chitosan and chitosan derivatives in drug delivery and tissue engineering. Adv Polym Sci 244: 19-44. doi: 10.1007/12_2011_137
![]() |
[71] |
Giri TK, Thakur A, Alexander A, et al. (2012) Modified chitosan hydrogels ad drug delivery and tissue engineering system: present status and application. Acta Pharm Sin B 2: 439-449. doi: 10.1016/j.apsb.2012.07.004
![]() |
[72] |
Berger J, Reist M, Mayer JM, et al. (2004) Structure and interactions in covalently and ionicallycrosslinked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm 57: 19-34. doi: 10.1016/S0939-6411(03)00161-9
![]() |
[73] |
Cai H, Zhang ZP, Sun PC, et al. (2005) Synthesis and characterization of thermo-and pH-sensitive hydrogels based on Chitosan-grafted N-isopropylacrylamide via γ-radiation. Rad Phys Chem 74: 26-30. doi: 10.1016/j.radphyschem.2004.10.007
![]() |
[74] |
El-Sherbiny IM, Smyth HDC (2010) Poly(ethylene glycol)-carboxymethyl chitosan-based pH-responsive hydrogels: photo-induced synthesis, characterization, swelling, and in vitro evaluation as potential drug carriers. Carbohydr Res 345: 2004-2012. doi: 10.1016/j.carres.2010.07.026
![]() |
[75] | Yamada K, Chen T, Kumar G, et al. (2000) Chitosan Based Water-Resistant Adhesive. Analogy to Mussel Glue. Biomacromolecules 1: 252-8. |
[76] |
Il'ina AV, Varlamov VP (2005) Chitosan-based polyelectrolyte complexes: A review. Appl Biochem Micro 41: 5-11. doi: 10.1007/s10438-005-0002-z
![]() |
[77] |
Lu Y, Sun W, Gu Z (2014) Stimuli responsive nanomaterials for therapeutic protein delivery. J Controlled Release 194: 1-19. doi: 10.1016/j.jconrel.2014.08.015
![]() |
[78] |
Haug A, Larsen B, Smidsrød O (1963) The degradation of alginate at different pH values. Acta Chem Scand 17: 1466. doi: 10.3891/acta.chem.scand.17-1466
![]() |
[79] | Timell TE (1964) The acid Hydrolysis of glycosides I. General conditions and the effect of the nature of the aglycone. Can J Chem 42: 1456-1472. |
[80] |
Haug A, Larsen B, Smidsrød O (1967) Alkaline degradation of alginate. Acta Chem Scand 21: 2859-2870. doi: 10.3891/acta.chem.scand.21-2859
![]() |
[81] |
Smidsrød O, Haug A, Larsen B (1967) Oxidative-reductive depolymerization: a note on the comparison of degradation rates of different polymers by viscosity measurements. Carbohydr Res 5: 482-485. doi: 10.1016/S0008-6215(00)81123-4
![]() |
[82] |
Holme HK, Foros H, Pettersen H, et al. (2001) Thermal depolymerization of chitosan chloride. Carbohydr Polym 46: 287-294. doi: 10.1016/S0144-8617(00)00332-5
![]() |
[83] |
Vårum KM, Ottøy MH, Smidsrød O (2001) Acid hydrolysis of chitosans. Carbohydr Polym 46: 89-98. doi: 10.1016/S0144-8617(00)00288-5
![]() |
[84] |
Menchicchi B, Fuenzalida JP, Bobbili KB, et al. (2014) Structure of chitosan determines its interactions with mucin. Biomacromolecules 15: 3550-3558. doi: 10.1021/bm5007954
![]() |
[85] |
Chen S, Cao Y, Ferguson LR, et al. (2013) Evaluation of mucoadhesive coatings of chitosan and thiolated chitosan for the colonic delivery of microencapsulated probiotic bacteria. J Microencapsu 30: 103-115. doi: 10.3109/02652048.2012.700959
![]() |
[86] | Rubinstein A (2005) Colon drug delivery. Drug Discov Today: Technol 2: 33-37. |
[87] |
Vandamme TF, Lenourry A, Charrueau C, et al. (2002) The use of polysaccharides to target drugs to the colon. Carbohydr Polym 48: 219-231. doi: 10.1016/S0144-8617(01)00263-6
![]() |
[88] |
Wong TY, Preston LA, Schiller NL (2000) ALGINATE LYASE: Review of Major Sources and Enzyme Characteristics, Structure-Function Analysis, Biological Roles, and Applications. Ann Rev Microbiol 54: 289-340. doi: 10.1146/annurev.micro.54.1.289
![]() |
[89] |
Gacesa P (1988) Alginates. Carbohydr Polym 8: 161-182. doi: 10.1016/0144-8617(88)90001-X
![]() |
[90] |
Wargacki AJ, Leonard E, Win MN, et al. (2012) An Engineered Microbial Platform for Direct Biofuel Production from Brown Macroalgae. Science 335: 308-313. doi: 10.1126/science.1214547
![]() |
[91] |
Kean T, Thanou M (2010) Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 62: 3-11. doi: 10.1016/j.addr.2009.09.004
![]() |
[92] |
Funkhouser JD, Aronson NN (2007) Chitinase family GH18: evolutionary insights from the genomic history of a diverse protein family. BMC Evol Biol 7: 96. doi: 10.1186/1471-2148-7-96
![]() |
[93] |
Nordtveit RJ, Vårum KM, Smidsrød O (1994) Degradation of fully water-soluble, partially N-acetylated chitosans with lysozyme. Carbohydr Polym 23: 253-260. doi: 10.1016/0144-8617(94)90187-2
![]() |
[94] |
Brouwer J, van Leeuwen-Herberts T, Otting-van de Ruit M (1984) Determination of lysozyme in serum, urine, cerebrospinal fluid and feces by enzyme immunoassay. Clin Chim Acta 142: 21-30. doi: 10.1016/0009-8981(84)90097-4
![]() |
[95] |
Vårum KM, Myhr MM, Hjerde RJN, et al. (1997) In vitro degradation rates of partially N-acetylated chitosans in human serum. Carbohydr Res 299: 99-101. doi: 10.1016/S0008-6215(96)00332-1
![]() |
[96] |
Deckers D, Vanlint D, Callewaert L, et al. (2008) Role of the Lysozyme Inhibitor Ivy in Growth or Survival of Escherichia coli and Pseudomonas aeruginosa Bacteria in Hen Egg White and in Human Saliva and Breast Milk. Appl Environ Microbiol 74: 4434-4439. doi: 10.1128/AEM.00589-08
![]() |
[97] |
Callewaert L, Michiels CW (2010) Lysozyme in animal kingdom. J Biosci 35: 127-160. doi: 10.1007/s12038-010-0015-5
![]() |
[98] |
Cohen JS (1969) Proton Magnetic Resonance Studies of Human Lysozyme. Nature 223: 43-46. doi: 10.1038/223043a0
![]() |
[99] |
Kristiansen A, Vårum KM, Grasdalen H (1998) The interactions between highly de-N-acetylated chitosans and lysozyme from chicken egg white studied by 1H-NMR spectroscopy. Eur J Biochem 251: 335-342. doi: 10.1046/j.1432-1327.1998.2510335.x
![]() |
[100] |
Sasaki C, Kristiansen A, Fukamizo T, et al. (2003) Biospecific Fractionation of Chitosan. Biomacromolecules 4: 1686-1690. doi: 10.1021/bm034124q
![]() |
[101] |
Ren D, Yi H, Wang W, et al. (2005) The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylaton. Carbohydr Res 340: 2403-2410. doi: 10.1016/j.carres.2005.07.022
![]() |
[102] |
Yang YM, Hu W, Wang XD, et al. (2007) The controlling biodegradation of chitosan fibers by n-acetylation in vitro and in vivo. J Mater Sci Mater Med 18: 2117-2121. doi: 10.1007/s10856-007-3013-x
![]() |
[103] |
Han T, Nwe N, Furuike T, et al. (2012) Methods of N-acetylated chitosan scaffolds and its in vitro biodegradation by lysozyme. J Biomed Sci Eng 5: 15-23. doi: 10.4236/jbise.2012.51003
![]() |
[104] |
Vårum KM, Holme HK, Izume M, et al. (1996) Determination of enzymatic hydrolysis specificity of partially N-acetylated chitosans. Biochem Biophy Acta (BBA) 1291: 5-15. doi: 10.1016/0304-4165(96)00038-4
![]() |
[105] | Wen X, Kellum JA (2012) N-Acetyl-beta-D-Glucosaminidase (NAG). Encyclopedia Intensive Care Medicine 1509-1510. |
[106] | Lim SM, Song DK, Oh SH, et al. (2008) In vitro and in vivo degradation behavior of acetylated chitosan porous beads. J Biomater Sci Polym Ed 19: 453-466. |
[107] |
Bajaj P, Schweller RM, Khademhosseini A, et al. (2014) 3D Biofabrication Strategies for Tissue Engineering and Regenerative Medicine. Annu Rev Biomed Eng 16: 247-276. doi: 10.1146/annurev-bioeng-071813-105155
![]() |
[108] |
Guarino V, Cirillo V, Altobelli R, et al. (2015) Polymer-based platforms by electric field-assisted techniques for tissue engineering and cancer therapy. Expert Rev Med Devices 12: 113-29. doi: 10.1586/17434440.2014.953058
![]() |
[109] | Li Z, Zhang M (2005) Chitosan-alginate as scaffolding material for cartilage tissue engineering. J Biomed Mater Res A 75: 485-493. |
[110] |
Phan-Lai V, Florczyk SJ, Kievit FM (2013) Three-Dimensional Scaffolds to Evaluate Tumor Associated Fibroblast-Mediated Suppression of Breast Tumor Specific T Cells. Biomacromolecules 14: 1330-1337. doi: 10.1021/bm301928u
![]() |
[111] |
Florczyk SJ, Liu G, Kievit FM, et al. (2012) 3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro. Adv Healthc Mater 1: 590-599. doi: 10.1002/adhm.201100054
![]() |
[112] |
Kievit FM Florczyk SJ, Leung MC, et al. (2010) Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. Biomaterials 31: 5903-5910. doi: 10.1016/j.biomaterials.2010.03.062
![]() |
[113] |
Mura S, Nicolas J, Couvreur P (2013) Stimuli-Responsive Nanocarriers for Drug Delivery. Nat Mater 12: 991-1003. doi: 10.1038/nmat3776
![]() |
[114] |
Gonçalves M, Figueira P, Maciel D (2014) pH-sensitive Laponite®/doxorubicin/alginate nanohybrids with improved anticancer efficacy. Acta Biomater 10: 300-307 doi: 10.1016/j.actbio.2013.09.013
![]() |
[115] |
Kim CK, Lee EJ (1992) The controlled release of blue dextran from alginate beads. Int J Pharm 79: 11-19. doi: 10.1016/0378-5173(92)90088-J
![]() |
[116] |
Gulbake A, Jain SK (2012) Chitosan: a potential polymer for colon-specific drug delivery system. Exp Opin Drug Deliv 9: 713-729. doi: 10.1517/17425247.2012.682148
![]() |
[117] |
Ganguly K, Aminabhavi TM, Kulkarni AR (2011) Colon Targeting of 5-Fluorouracil Using Polyethylene Glycol Cross-linked Chitosan Microspheres Enteric Coated with Cellulose Acetate Phthalate. Ind Eng Chem Res 50: 11797-11807. doi: 10.1021/ie201623d
![]() |
[118] | Lai CK, Lu YL, Hsieh JT, et al. (2014), Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy. Nanomedicine 9: 803-817. |
[119] | Arora S, Budhiraja RD (2012) Chitosan-alginate microcapsules of amoxicillin for gastric stability and mucoadhesion. J Adv Pharm Techno Res 3: 68-74. |
[120] |
Du J, Dai J, Liu JL, et al. (2006) Novel pH-sensitive polyelectrolyte carboxymethyl Konjac glucomannan-chitosan beads as drug carriers. React Funct Polym 66: 1055-1061. doi: 10.1016/j.reactfunctpolym.2006.01.014
![]() |
[121] | Liu Z, Jiao Y, Liu F, et al. (2007) Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation. J Biomed Mater Res Part A 83: 806-812. |
[122] | Zhou T, Xiao C, Fan J, et al. (2012) A nanogel of on-site tunable pH-response for efficient anticancer drug delivery. Acta Biomater 9: 4546-4557. |
[123] |
Kutlu C, Çakmak AS, Gümüşderelioğlu M (2014) Double-effective chitosan scaffold-PLGA nanoparticle system for brain tumour therapy: in vitro study. J Microencapsul 31: 700-707. doi: 10.3109/02652048.2014.913727
![]() |
[124] | Feng C, Song R, Sun G, et al. (2014) Immobilization of Coacervate Microcapsules in Multilayer Sodium Alginate Beads for Efficient Oral Anticancer Drug Delivery. Biomacromolecules15: 985-996. |
[125] | Anchisi C, Meloni MC, Maccioni AM (2006) Chitosan beads loaded with essential oils in cosmetic formulations. J Cosmet Sci 57: 205-214. |
[126] |
Ariza-Avidad M, Nieto A, Salinas-Castillo A, et al. (2014) Monitoring of degradation of porous silicon photonic crystals using digital photograph. Nanoscale Res Lett 9: 410. doi: 10.1186/1556-276X-9-410
![]() |
[127] |
Jung SM, Yoon GH, Lee HC, et al. (2015) Chitosan nanoparticle/PCL nanofiber composite for wound dressing and drug delivery. J Biomater Sci Polym 26: 252-263. doi: 10.1080/09205063.2014.996699
![]() |
[128] | Badawy ME, El-Aswad AF (2014) Bioactive paper sensor based on the acetylcholinesterase for the rapid detection of organophosphate and carbamate pesticides. Int J Anal Chem 2014 Article ID 536823. |
[129] | Spreen KA, Zikakis JP, Austin PR (1984) Chitin, Chitosan and Related Enzymes. In J P Zikakis (Ed.) Academic Press, Orlando, 57. |
[130] | Vázquez N, Chacón M, Meana Á, et al. (2015) Keratin-chitosan membranes as scaffold for tissue engineering of human cornea. Histol Histopathol 30: 813-821. |
[131] |
Cheng YH, Hung KH, Tsai TH, et al. (2014) Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension. Acta Biomater 10: 4360-4366. doi: 10.1016/j.actbio.2014.05.031
![]() |
[132] |
Wu FC, Tseng RL, Juang RS (2010) A review and experimental verification of using chitosan and its derivatives as adsorbents for selected heavy metals. J Environ Manage 91: 798-806. doi: 10.1016/j.jenvman.2009.10.018
![]() |
[133] |
Szymańska E, Winnicka K, AmelianA, et al. (2014) Vaginal chitosan tablets with clotrimazole-design and evaluation of mucoadhesive properties using porcine vaginal mucosa, mucin and gelatin. Chem Pharm Bull (Tokyo) 62:160-167. doi: 10.1248/cpb.c13-00689
![]() |
[134] |
Rao TV, Kumar GK, Ahmed MG, et al. (2012) Development and evaluation of chitosan based oral controlled matrix tablets of losartan potassium. Int J Pharm Investig 2: 157-161. doi: 10.4103/2230-973X.104399
![]() |
[135] |
Wassmer S, Rafat M, Fong WG, et al. (2013) Chitosan microparticles for delivery of proteins to the retina. Acta Biomater 9: 7855-7864. doi: 10.1016/j.actbio.2013.04.025
![]() |
[136] |
Chen CK, Wang Q, Jones CH, et al. (2014) Synthesis of pH-responsive chitosan nanocapsules for the controlled delivery of doxorubicin. Langmuir 30: 4111-4119. doi: 10.1021/la4040485
![]() |
[137] | Prasad M, Palanivelu P (2014) Immobilization of a thermostable, fungal recombinant chitinase on biocompatible chitosan beads and the properties of the immobilized enzyme. Biotechnol Appl Biochem 62: 523-529. |
[138] |
Jain SK, Chourasia MK, Sabitha M, et al. (2003) Development and characterization of transdermal drug delivery systems for diltiazem hydrochloride. Drug Deliv 10: 169-177. doi: 10.1080/713840400
![]() |
[139] |
Kong M, Chen XG, Xing K, et al. (2010) Antimicrobial properties of chitosan and mode of action: a state of the art review. Int J Food Microbiol 144: 51-63. doi: 10.1016/j.ijfoodmicro.2010.09.012
![]() |
[140] |
Yang J, Luo K, Li D, et al. (2013) Preparation, characterization and in vitro anticoagulant activity of highly sulfated chitosan. Int J Biol Macromol 52: 25-31. doi: 10.1016/j.ijbiomac.2012.09.027
![]() |
[141] |
Whang HS, Kirsch W, Zhu YH, et al. (2005) Hemostatic Agents Derived from Chitin and Chitosan. J Macromol Sci Part C: Polym Rev 45: 309-323. doi: 10.1080/15321790500304122
![]() |
[142] |
Čopíková J, Taubner T, Tůma J, et al. (2015) Cholesterol and fat lowering with hydrophobic polysaccharide derivatives. Carbohydr Polym 116: 207-214. doi: 10.1016/j.carbpol.2014.05.009
![]() |
[143] | Pereira GG, Guterres SS, Balducci AG, et al. (2014) Polymeric films loaded with vitamin E and aloe vera for topical application in the treatment of burn wounds. Biomed Res Int 2014 ID 641590. |
[144] |
Rojas-Graü MA, Tapia MS, Rodríguez FJ, et al. (2007) Alginate and gellan based edible coatings as support of antibrowning agents applied on fresh-cut Fuji apple. Food Hydrocolloids 21: 118-127. doi: 10.1016/j.foodhyd.2006.03.001
![]() |
[145] |
Wargacki AJ, Leonard E, Win MN, et al. (2012) An engineered microbial platform for direct biofuel production from brown macroalgae. Science 335: 308-313. doi: 10.1126/science.1214547
![]() |
[146] |
Sarei F, Dounighi NM, Zolfagharian H, et al. (2013) Alginate Nanoparticles as a Promising Adjuvant and Vaccine Delivery System. Indian J Pharm Sci 75: 442-449. doi: 10.4103/0250-474X.119829
![]() |
[147] |
Tønnesen HH, Karlsen J (2002) Alginate in Drug Delivery Systems. Drug Dev Ind Pharm 28: 621-630. doi: 10.1081/DDC-120003853
![]() |
[148] |
Giri TK, Thakur D, Alexander A, et al. (2012) Alginate based Hydrogel as a Potential Biopolymeric Carrier for Drug Delivery and Cell Delivery Systems: Present Status and Applications. Curr Drug Deliv 9: 539-555. doi: 10.2174/156720112803529800
![]() |
[149] |
Murata Y, Sasaki N, Miyamoto E, et al. (2000) Use of floating alginate gel beads for stomach-specific drug deliver. Eur J Pharm Biopharm 50: 221-226. doi: 10.1016/S0939-6411(00)00110-7
![]() |
[150] | Paul W, Sharma CP (2004) Chitosan and Alginate Wound Dressings: A Short Review. Trends Biomater Artif Organs 18: 18-23. |
[151] |
Tanga M, Chena W, Weira MD, et al. (2012) Human embryonic stem cell encapsulation in alginate microbeads in macroporous calcium phosphate cement for bone tissue engineering. Acta Biomater 8: 3436-3445. doi: 10.1016/j.actbio.2012.05.016
![]() |
[152] |
Martinez JC, Kim JW, Ye C, et al. (2012) A Microfluidic Approach to Encapsulate Living Cells in Uniform Alginate Hydrogel Microparticles. Macromol Biosci 12:946-951. doi: 10.1002/mabi.201100351
![]() |
[153] | Yang Q, Lei S (2014) Alginate Dressing Application in Hemostasis After Using Seldinger Peripherally Inserted Central Venous Catheter in Tumor Patients. Indian J Hematol Blood Transfus DOI 10.1007/s12288-014-0490-1. |
[154] |
Kimura Y, Watanabe K, Okuda H (1996) Effects of soluble sodium alginate on cholesterol excretion and glucose tolerance in rats. J Ethnopharmacol 54: 47-54. doi: 10.1016/0378-8741(96)01449-3
![]() |
[155] |
Ueno M, Tamura Y, Toda N, et al. (2012) Sodium Alginate Oligosaccharides Attenuate Hypertension in Spontaneously Hypertensive Rats Fed a Low-Salt Diet. Clin Exp Hypertens 34: 305-310. doi: 10.3109/10641963.2011.577484
![]() |
[156] | Odunsi ST, Vázquez-Roque MI, Camilleri M (2009) Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity 18: 1579-1584. |
[157] | Bhunchu S, Rojsitthisak P (2014) Biopolymeric alginate-chitosan nanoparticles as drug delivery carriers for cancer therapy. Pharmazie 69: 563-570. |
[158] |
Idota Y, Harada H, Tomono T, et al. (2013) Alginate Enhances Excretion and Reduces Absorption of Strontium and Cesium in Rats. Biol Pharm Bull 36: 485-491. doi: 10.1248/bpb.b12-00899
![]() |
1. | Rinaldo M. Colombo, Mauro Garavello, Well Posedness and Control in a NonLocal SIR Model, 2020, 0095-4616, 10.1007/s00245-020-09660-9 | |
2. | Rinaldo M. Colombo, Mauro Garavello, Francesca Marcellini, Elena Rossi, An age and space structured SIR model describing the Covid-19 pandemic, 2020, 10, 2190-5983, 10.1186/s13362-020-00090-4 | |
3. | Hiroya Kikuchi, Hiroaki Mukaidani, Ramasamy Saravanakumar, Weihua Zhuang, 2020, Robust Vaccination Strategy based on Dynamic Game for Uncertain SIR Time-Delay Model, 978-1-7281-8526-2, 3427, 10.1109/SMC42975.2020.9283389 | |
4. | Giacomo Albi, Lorenzo Pareschi, Mattia Zanella, Modelling lockdown measures in epidemic outbreaks using selective socio-economic containment with uncertainty, 2021, 18, 1551-0018, 7161, 10.3934/mbe.2021355 | |
5. | Giacomo Albi, Lorenzo Pareschi, Mattia Zanella, Control with uncertain data of socially structured compartmental epidemic models, 2021, 82, 0303-6812, 10.1007/s00285-021-01617-y | |
6. | Christian John Hurry, Alexander Mozeika, Alessia Annibale, Vaccination with partial transmission and social distancing on contact networks, 2022, 2022, 1742-5468, 033302, 10.1088/1742-5468/ac50ae | |
7. | Martin Kröger, Mustafa Turkyilmazoglu, Reinhard Schlickeiser, Explicit formulae for the peak time of an epidemic from the SIR model. Which approximant to use?, 2021, 425, 01672789, 132981, 10.1016/j.physd.2021.132981 | |
8. | Emanuele Bernardi, Lorenzo Pareschi, Giuseppe Toscani, Mattia Zanella, Effects of Vaccination Efficacy on Wealth Distribution in Kinetic Epidemic Models, 2022, 24, 1099-4300, 216, 10.3390/e24020216 | |
9. | Reinhard Schlickeiser, Martin Kröger, Analytical Modeling of the Temporal Evolution of Epidemics Outbreaks Accounting for Vaccinations, 2021, 3, 2624-8174, 386, 10.3390/physics3020028 | |
10. | Erivelton G. Nepomuceno, Márcia L. C. Peixoto, Márcio J. Lacerda, Andriana S. L. O. Campanharo, Ricardo H. C. Takahashi, Luis A. Aguirre, Application of Optimal Control of Infectious Diseases in a Model-Free Scenario, 2021, 2, 2662-995X, 10.1007/s42979-021-00794-3 | |
11. | Alejandro Carballosa, José Balsa-Barreiro, Pablo Boullosa, Adrián Garea, Jorge Mira, Ángel Miramontes, Alberto P. Muñuzuri, Assessing the risk of pandemic outbreaks across municipalities with mathematical descriptors based on age and mobility restrictions, 2022, 160, 09600779, 112156, 10.1016/j.chaos.2022.112156 | |
12. | Candy Sonveaux, Joseph J. Winkin, State feedback control law design for an age-dependent SIR model, 2023, 158, 00051098, 111297, 10.1016/j.automatica.2023.111297 | |
13. | Fernando Córdova-Lepe, Juan Pablo Gutiérrez-Jara, A Dynamic Reaction-restore-type Transmission-rate Model for COVID-19, 2024, 21, 2224-2902, 118, 10.37394/23208.2024.21.12 |
$ \bar a $ in (2.3) | 0.1 | 0.2 | 0.3 | 0.5 | 1.0 | 1.5 | none |
$ \mathcal{J} $ in (1.8) | 33.48 | 41.03 | 44.73 | 46.85 | 47.39 | 47.51 | 48.30 |
$ \mathcal{N} $ in (1.5) | 10.53 | 5.05 | 2.30 | 0.76 | 0.41 | 0.36 | 0.00 |
$ \mathcal{J}+\mathcal{N} $ in (1.9) | 44.01 | 46.08 | 47.03 | 47.61 | 47.80 | 47.87 | 48.30 |
$ \bar t $ in (2.4) | 0.1 | 0.2 | 0.3 | 0.5 | 1.0 | 1.5 | none |
$ \mathcal{J} $ in (1.8) | 31.71 | 38.80 | 43.65 | 46.79 | 47.40 | 47.42 | 48.30 |
$ \mathcal{N} $ in (1.7) | 9.37 | 5.46 | 2.74 | 0.86 | 0.40 | 0.39 | 0.00 |
$ \mathcal{J}+\mathcal{N} $ in (1.10) | 41.08 | 44.26 | 46.39 | 47.66 | 47.80 | 47.80 | 48.30 |
$ \eta_1 $ | $ \eta_2 $ | $ \eta_3 $ | $ \mathcal{J} $ as in (1.8) | $ \mathcal{N} $ as in (1.5) | $ \mathcal{J} + \mathcal{N} $ as in (1.9) |
$ 0.6 $ | $ 0.6 $ | $ 0.6 $ | $ 14.54 $ | $ 7.56 $ | $ 22.11 $ |
$ 0.6 $ | $ 0.6 $ | $ 0.8 $ | $ 14.38 $ | $ 7.87 $ | $ 22.25 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.6 $ | $ 14.18 $ | $ 8.02 $ | $ 22.20 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.8 $ | $ 14.02 $ | $ 8.31 $ | $ 22.83 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.6 $ | $ 13.12 $ | $ 9.22 $ | $ 22.34 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.8 $ | $ 12.96 $ | $ 9.52 $ | $ 22.48 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.6 $ | $ 12.80 $ | $ 9.60 $ | $ 22.40 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.8 $ | $ 12.64 $ | $ 9.88 $ | $ 22.53 $ |
see Figure 8 | $ 16.01 $ | $ 4.67 $ | $ 20.69 $ |
$ \nu_1 $ | $ \nu_2 $ | $ \nu_3 $ | $ \mathcal{J} $ as in (1.8) | $ \mathcal{N} $ as in (1.7) | $ \mathcal{J} + \mathcal{N} $ as in (1.10) |
$ 0.6 $ | $ 0.6 $ | $ 0.6 $ | $ 6.41 $ | $ 13.05 $ | $ 19.47 $ |
$ 0.6 $ | $ 0.6 $ | $ 0.8 $ | $ 6.23 $ | $ 13.75 $ | $ 19.98 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.6 $ | $ 6.17 $ | $ 13.60 $ | $ 19.77 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.8 $ | $ 6.06 $ | $ 14.10 $ | $ 20.16 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.6 $ | $ 5.78 $ | $ 13.89 $ | $ 19.66 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.8 $ | $ 5.67 $ | $ 14.44 $ | $ 20.12 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.6 $ | $ 5.66 $ | $ 14.22 $ | $ 19.88 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.8 $ | $ 5.59 $ | $ 14.65 $ | $ 20.24 $ |
see Figure 11 | $ 7.80 $ | $ 8.18 $ | $ 15.98 $ |
$ \bar a $ in (2.3) | 0.1 | 0.2 | 0.3 | 0.5 | 1.0 | 1.5 | none |
$ \mathcal{J} $ in (1.8) | 33.48 | 41.03 | 44.73 | 46.85 | 47.39 | 47.51 | 48.30 |
$ \mathcal{N} $ in (1.5) | 10.53 | 5.05 | 2.30 | 0.76 | 0.41 | 0.36 | 0.00 |
$ \mathcal{J}+\mathcal{N} $ in (1.9) | 44.01 | 46.08 | 47.03 | 47.61 | 47.80 | 47.87 | 48.30 |
$ \bar t $ in (2.4) | 0.1 | 0.2 | 0.3 | 0.5 | 1.0 | 1.5 | none |
$ \mathcal{J} $ in (1.8) | 31.71 | 38.80 | 43.65 | 46.79 | 47.40 | 47.42 | 48.30 |
$ \mathcal{N} $ in (1.7) | 9.37 | 5.46 | 2.74 | 0.86 | 0.40 | 0.39 | 0.00 |
$ \mathcal{J}+\mathcal{N} $ in (1.10) | 41.08 | 44.26 | 46.39 | 47.66 | 47.80 | 47.80 | 48.30 |
$ \eta_1 $ | $ \eta_2 $ | $ \eta_3 $ | $ \mathcal{J} $ as in (1.8) | $ \mathcal{N} $ as in (1.5) | $ \mathcal{J} + \mathcal{N} $ as in (1.9) |
$ 0.6 $ | $ 0.6 $ | $ 0.6 $ | $ 14.54 $ | $ 7.56 $ | $ 22.11 $ |
$ 0.6 $ | $ 0.6 $ | $ 0.8 $ | $ 14.38 $ | $ 7.87 $ | $ 22.25 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.6 $ | $ 14.18 $ | $ 8.02 $ | $ 22.20 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.8 $ | $ 14.02 $ | $ 8.31 $ | $ 22.83 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.6 $ | $ 13.12 $ | $ 9.22 $ | $ 22.34 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.8 $ | $ 12.96 $ | $ 9.52 $ | $ 22.48 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.6 $ | $ 12.80 $ | $ 9.60 $ | $ 22.40 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.8 $ | $ 12.64 $ | $ 9.88 $ | $ 22.53 $ |
see Figure 8 | $ 16.01 $ | $ 4.67 $ | $ 20.69 $ |
$ \nu_1 $ | $ \nu_2 $ | $ \nu_3 $ | $ \mathcal{J} $ as in (1.8) | $ \mathcal{N} $ as in (1.7) | $ \mathcal{J} + \mathcal{N} $ as in (1.10) |
$ 0.6 $ | $ 0.6 $ | $ 0.6 $ | $ 6.41 $ | $ 13.05 $ | $ 19.47 $ |
$ 0.6 $ | $ 0.6 $ | $ 0.8 $ | $ 6.23 $ | $ 13.75 $ | $ 19.98 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.6 $ | $ 6.17 $ | $ 13.60 $ | $ 19.77 $ |
$ 0.6 $ | $ 0.8 $ | $ 0.8 $ | $ 6.06 $ | $ 14.10 $ | $ 20.16 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.6 $ | $ 5.78 $ | $ 13.89 $ | $ 19.66 $ |
$ 0.8 $ | $ 0.6 $ | $ 0.8 $ | $ 5.67 $ | $ 14.44 $ | $ 20.12 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.6 $ | $ 5.66 $ | $ 14.22 $ | $ 19.88 $ |
$ 0.8 $ | $ 0.8 $ | $ 0.8 $ | $ 5.59 $ | $ 14.65 $ | $ 20.24 $ |
see Figure 11 | $ 7.80 $ | $ 8.18 $ | $ 15.98 $ |